ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2010
Multiple genetic variants in telomere pathway genes and breast cancer risk.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 5 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Human TERT promoter polymorphism rs2853669 is associated with cancers: an updated meta-analysis.Human cell · 2021Pooled it
- Association between TERT rs2853669 polymorphism and cancer risk: A meta-analysis of 9,157 cases and 11,073 controls.PloS one · 2018Pooled it
- Telomere reverse transcriptase (TERT) rs2735940 increases cancer risk.Medical science monitor : international medical journal of experimental and clinical research · 2015Pooled it
- Telomerase reverse transcriptase locus polymorphisms and cancer risk: a field synopsis and meta-analysis.Journal of the National Cancer Institute · 2012Pooled it
- Pooled it
- Candidate locus analysis of the TERT-CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk.Human genetics · 2015Trial
- Breast cancer phenotypes in carriers of pathogenic POT1 variants.Familial cancer · 2026Article
- Long-Read Amplicon Sequencing for the Detection of TERT Promoter Variant Clonal Hematopoiesis in Patients with Telomere Biology Disorders.The Journal of molecular diagnostics : JMD · 2026Article
- Genetic and epigenetic alterations in night shift nurses with breast cancer: a narrative review.Cancer cell international · 2025Review
- Regulation and clinical potential of telomerase reverse transcriptase (TERT/hTERT) in breast cancer.Cell communication and signaling : CCS · 2023Review
- Telomere Length as a New Risk Marker of Early-Onset Colorectal Cancer.International journal of molecular sciences · 2023Article
- Genetic Variants of the TERT Gene and Telomere Length in Obstructive Sleep Apnea.Biomedicines · 2022Article
- Telomeres and Cancer.Life (Basel, Switzerland) · 2021Review
- Large Multicohort Study Reveals a Prostate Cancer Susceptibility Allele at 5p15 RegulatingFrontiers in oncology · 2021Article
- Role of POT1 in Human Cancer.Cancers · 2020Review
- Association between functional TERT promoter polymorphism rs2853669 and cervical cancer risk in South Indian women.Molecular and clinical oncology · 2020Article
- Telomere Maintenance Mechanisms in Cancer.Genes · 2018Review
- Exercise, Telomeres, and Cancer: "The Exercise-Telomere Hypothesis".Frontiers in physiology · 2018Review
- Association between rs2853669 in TERT gene and the risk and prognosis of human cancer: a systematic review and meta-analysis.Oncotarget · 2017Article
- Mechanisms of breast cancer risk in shift workers: association of telomere shortening with the duration and intensity of night work.Cancer medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
purposeTo explore the etiologic role of genetic variants in telomere pathway genes and breast cancer risk.
methodsA population-based case-control study, the Long Island Breast Cancer Study Project, was conducted, and 1,067 cases and 1,110 controls were included in the present study. Fifty-two genetic variants of nine telomere-related genes were genotyped.
resultsSeven single nucleotide polymorphisms (SNP) showed significant case-control differences at the level of P < 0.05. The top three statistically significant SNPs under a dominant model were TERT-07 (rs2736109), TERT-54 (rs3816659), and POT1-03 (rs33964002). The odds ratios (OR) were 1.56 [95% confidence interval (95% CI), 1.22-1.99] for the TERT-07 G-allele, 1.27 (95% CI, 1.05-1.52) for the TERT-54 T-allele, and 0.79 (95% CI, 0.67-0.95) for the POT1-03 A-allele. TERT-67 (rs2853669) was statistically significant under a recessive model; the OR of the CC genotype was 0.69 (95% CI, 0.69-0.93) compared with the T-allele. However, none of the SNPs retained significance after Bonferroni adjustment for multiple testing at the level of P < 0.001 (0.05/52) except for TERT-07. When restricted to Caucasians (94% of the study subjects), a stronger association for the TERT-07 G-allele was observed with an OR of 1.60 (95% CI, 1.24-2.05; P = 0.0002). No effect modifications were found for variant alleles and menopausal status, telomere length, cigarette smoking, body mass index status, and family history of breast cancer risk.
conclusionsFour SNPs in the TERT and POT1 genes were significantly related with overall breast cancer risk. This initial analysis provides valuable clues for further exploration of the biological role of telomere pathway genes in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.